Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial
Authors
Yuanji Xu
Xiaomin Wang (ORCID: https://orcid.org/0000-0003-0336-5526)
Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial
Yuanji Xu, Xiaomin Wang, Zhiyong Zheng, Shi‐Hong Luo et al.
Citations
3 citations
Journal
Radiation Oncology
Topics
Esophageal Cancer Research and Treatment
Field-Weighted Citation Impact (FWCI)
6.02
article
Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial
Fujian Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Wenzhou Medical University (CN), National Cancer Center (US), First Affiliated Hospital of Xinxiang Medical University (CN), Ningxia Medical University (CN), Ningxia Medical University General Hospital (CN), Affiliated Hospital of Hebei University (CN), Fujian Provincial Cancer Hospital (CN), Affiliated Hospital of Jining Medical University (CN), Anyang Tumor Hospital (CN), Henan Medical University (CN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial — Yuanji Xu, Xiaomin Wang, et al. · Radiation Oncology (2025) | TGRS Research Map | TGRS